RxLedger: Medicare Part D drug spending
What Medicare Part D spends on every drug — total spend, per dose, per claim and per beneficiary.
In 2023 (the latest CMS data year), the Medicare Part D program spent about $275.92B across 3,598 drugs and 1,617,636,450 claims. The single biggest line was Eliquis (Apixaban) at $18,273,451,967, followed by Ozempic (Semaglutide) ($9,194,048,435) and Jardiance (Empagliflozin) ($8,839,935,063). RxLedger breaks down total spend, spend per dosage unit, per claim and per beneficiary, claims, beneficiaries, manufacturer and year-over-year change for the 350 highest-spend drugs. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Top 10 drugs by total Medicare Part D spending (2023)
| Rank | Drug | Total spend 2023 | Per dosage unit | Beneficiaries | Spend YoY |
|---|---|---|---|---|---|
| #1 | Eliquis (Apixaban) | $18,273,451,967 | $9.74 | 3,927,848 | +20.1% |
| #2 | Ozempic (Semaglutide) | $9,194,048,435 | $355.90 | 1,464,468 | +98.7% |
| #3 | Jardiance (Empagliflozin) | $8,839,935,063 | $20.32 | 1,882,768 | +51.1% |
| #4 | Trulicity (Dulaglutide) | $7,363,856,224 | $483.21 | 938,731 | +18.3% |
| #5 | Xarelto (Rivaroxaban) | $6,309,246,823 | $18.23 | 1,324,165 | +9.3% |
| #6 | Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter) | $4,455,884,010 | $11.18 | 1,050,583 | +33.4% |
| #7 | Humira(Cf) Pen (Adalimumab) | $4,419,828,188 | $3,750.06 | 61,474 | +19.6% |
| #8 | Farxiga (Dapagliflozin Propanediol) | $4,342,182,307 | $19.55 | 993,909 | +68.0% |
| #9 | Januvia (Sitagliptin Phosphate) | $4,090,836,821 | $18.88 | 843,391 | -0.2% |
| #10 | Revlimid (Lenalidomide) | $3,859,804,789 | $878.21 | 36,967 | -35.0% |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
See the full biggest-spend ranking →
Explore the data
Browse 350 drug pages with full spending detail, plus every drug in the dataset.
RankingsBiggest total spend, highest per-dose, fastest-rising prices, highest per beneficiary, most claims.
ManufacturersThe 22 drug makers with the most Medicare Part D spending and their drugs.
MethodologyWhat "total spending" and "spending per dosage unit" mean, and how we use the CMS file.
Drugs with the fastest-rising price per dosage unit (2022→2023)
| Drug | Per-unit change YoY | Per dosage unit 2023 | Claims |
|---|---|---|---|
| Lagevrio (Eua) (Molnupiravir) | +204.8% | $0.75 | 383,878 |
| Euthyrox (Levothyroxine Sodium) | +47.4% | $0.14 | 108,762 |
| Piperacillin-Tazobactam (Piperacillin Sodium/Tazobactam) | +43.5% | $4.68 | 68,242 |
| Glipizide XL (Glipizide) | +38.6% | $0.33 | 75,839 |
| Meropenem | +34.7% | $4.26 | 87,893 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Full fastest-rising-price ranking →
Highest spend per dosage unit (2023)
| Drug | Per dosage unit | Total spend |
|---|---|---|
| Amvuttra (Vutrisiran Sodium) | $239,745.73 | $67,368,549 |
| Vabysmo (Faricimab-Svoa) | $46,702.42 | $14,996,148 |
| Givlaari (Givosiran Sodium) | $41,427.37 | $14,748,145 |
| Beovu (Brolucizumab-Dbll) | $40,425.23 | $602,256 |
| Eylea Hd (Aflibercept) | $40,244.02 | $656,380 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Full per-dosage-unit ranking →
Frequently asked questions
What is the Medicare Part D Spending by Drug dataset?
It is an official CMS dataset that reports how much the Medicare Part D prescription-drug program spent on each drug, plus average spending per dosage unit, per claim and per beneficiary, the number of claims and beneficiaries, the manufacturer and the year-over-year price change. The latest data year is 2023. Figures are aggregate program spending in the public domain — not the price an individual pays.
Which drug costs Medicare Part D the most?
In 2023, Eliquis (Apixaban) had the highest total Medicare Part D spending at $18,273,451,967, ahead of Ozempic (Semaglutide) ($9,194,048,435) and Jardiance (Empagliflozin) ($8,839,935,063). Source: CMS Medicare Part D Spending by Drug, data year 2023.
Are these the prices patients pay for drugs?
No. These are aggregate Medicare program figures — the total gross drug cost (Medicare, plan and beneficiary payments combined) and averages across all claims. What you pay depends on your plan, formulary, deductible and coverage phase. Always check your Part D plan and ask your pharmacist.
About this data
RxLedger publishes Medicare Part D drug-spending data from the official CMS Medicare Part D Spending by Drug dataset (data year 2023, U.S. public domain). Every page is static, loads instantly and shows its source. These are aggregate public-spending figures, not the price you pay and not medical or pricing advice. See our methodology and disclaimer.
Last updated: 2026-06-21